Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 285

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 285
---
 Trust Company, as warrant agent, and us. The warrant agreement provides
that the terms of the warrants may be amended without the consent of any shareholder or warrant holder to cure any ambiguity or correct
any defective provision or to make any amendments that are necessary in the good faith determination of our board of directors (taking
into account then existing market precedents) to allow for the warrants to be classified as equity in our financial statements (provided
that any modifications or amendments that would increase the warrant price or shorten the exercise period shall require the approval
of the warrant holders in accordance with the warrant agreement), but otherwise requires the approval by the holders of at least 65%
of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants;
provided that any amendment that solely affects the terms of the private placement warrants or any provision of the warrant agreement
solely with respect to the private placement warrants will also require at least 65% of the then outstanding private placement warrants.
Accordingly, we may amend the terms of the public warrants (i) in a manner adverse to a holder of public warrants if holders of at least
65% of the then outstanding public warrants approve of such amendment or (ii) to the extent necessary for the warrants in the good faith
determination of our board of directors (taking into account then existing market precedents) to allow for the warrants to be classified
as equity in our financial statements without the consent of any shareholder or warrant holder (provided that any modifications or amendments
that would increase the warrant price or shorten the exercise period shall require the approval of the warrant holders in accordance
with the warrant agreement). Although our ability to amend the terms of the public warrants with the consent of at least 65% of the then
outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise
price of the warrants, convert the warrants into cash or shares, shorten the exercise period or decrease the number of Class A ordinary
shares purchasable upon exercise of a warrant.

A provision of our warrant agreement may make it more difficult
for us to consummate an initial business combination. 

If (i) we issue additional ordinary shares or
equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at a Newly Issued
Price of less than $9.20 per Class A ordinary share, (ii) the aggregate gross proceeds from such issuances represent more than 60